Clinical Biochemistry – Updates to Prostate Specific Antigen (PSA) ranges
Printer-friendly versionClinical Biochemistry – Updates to Prostate Specific Antigen (PSA) ranges
From Monday 2nd February the Clinical Biochemistry department will make a change to the reference ranges reported for the Prostate Specific Antigen (PSA) test. The updated ranges are based on those in the NICE CKS on Prostate Cancer and are also in line with regional referral criteria for suspected prostate cancer.
|
Age (years) |
Current PSA upper reference limits (ug/L) |
NICE CKS referral guidance |
Proposed updated upper reference limits |
|
0 to 39 |
<2.5 |
Use clinical judgement |
No reported upper reference limit, but results >2.5 will be flagged in clinical systems |
|
40-49 |
<2.5 |
More than 2.5 |
2.5 |
|
50 to 59 |
<3.0 |
More than 3.5 |
3.5 |
|
60 to 69 |
<3.0 |
More than 4.5 |
4.5 |
|
70 to 79 |
<5.0 |
More than 6.5 |
6.5 |
|
80+ |
<10.0 |
More than 20 or more than 7.5 and there are symptoms suggestive of metastatic disease (bone pain and/or fatigue and/or significant unintended weight loss) |
7.5 |
If you would like any further information about this change, please contact the Clinical Biochemistry team by email (peh-tr.chemimm@nhs.net).
